SALKA SUSAN R 4

What Happened

• Susan R. Salka, a director of Teladoc Health, received an award of 48,638 restricted stock units (RSUs) on 2026-03-30. The Form 4 reports the grant as a derivative acquisition at $0.00 (total reported value $0), coded as an award/grant (A). This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-30; transaction type: Award/Grant (code A); reported price: $0.00.
• Shares/units granted: 48,638 RSUs (each RSU represents a contingent right to one share).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing date: 2026-04-01 (filed timely following the 2026-03-30 grant).
• Footnotes:
  • F1: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
  • F2: Vesting: one-third vests on the first anniversary of the grant date; the remainder vests in eight substantially equal quarterly installments thereafter.

Context

• These RSUs are a form of equity compensation for a director; they are derivative awards that convert to common stock only as they vest. There is no indication these shares were sold or exercised immediately — this filing documents the grant itself, not any market transactions.